$VTAK On 11/20 announced Catheter Precision's (VTAK) First Successful VIVO(TM) Cases Completed in Croatia Sets Stage for Expansion into South-Eastern Europe
Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a pioneering medical technology firm headquartered in the United States, specializing in electrophysiology devices, has proudly disclosed the successful conclusion of the inaugural VIVO cases in the region of South-Eastern Europe. VIVO, the Company's innovative 3D non-invasive imaging system, is used pre-procedurally to identify areas of interest for ventricular ablation and aid in pre-procedure planning to reduce procedure time and aid in procedural accuracy.
VIVO was assessed during four ventricular ablation procedures at Dubrava University Hospital in Zagreb, Croatia. Dr. Ivan Zeljkovic, Head of Electrophysiology Lab at Dubrava University Hospital stated, "The VIVO workflow is simple and flexible, and I was impressed with the accuracy of the VIVO maps which certainly exceeded my expectations! Having the VIVO maps pre-procedurally, allowed us to accurately target the anatomic location of the ventricular arrhythmia and has the potential to increase procedural efficacy."
"This is the first step to expanding VIVO's presence in South-Eastern Europe" stated Patricia Kennedy, Chief Commercialization Officer. "The evaluation yielded positive results, and we anticipate a purchase order soon. Dr. Zeljkovic reiterated what we have always known to be true about VIVO: it is accurate, easy to use, and non-invasive localization provided to the physician pre-procedurally has the potential to improve procedural outcomes."
finance.yahoo.com |
